Safety study of CT1182 for relapsed B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have B-cell non-Hodgkin lymphoma that has relapsed (returned) or become resistant to prior treatment
- You previously received standard chemotherapy including anti-CD20 drugs and anthracyclines
- Your cancer is measurable on CT scan or PET scan
- Your heart, liver, and kidney function meet certain minimum levels
- You have not received other experimental cell therapies or CD19-targeted treatments recently
- You are 18–75 years old with expected survival of at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This study tests a new therapy called CT1194C for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. It aims to see if the therapy is safe and effective.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This Phase 1/2 study tests CT120 in people with B-cell non-Hodgkin’s lymphoma that has come back (relapsed) or did not respond well (refractory) to previous treatment. The goal is to find a safe dose and see whether it can shrink tumors.
Hear when a new B-cell Non Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.